Louis Ploth - Moleculin Biotech Independent Advisor
| MBRX Stock | USD 2.73 0.10 3.53% |
Insider
Louis Ploth is Independent Advisor of Moleculin Biotech
| Age | 70 |
| Address | 5300 Memorial Drive, Houston, TX, United States, 77007 |
| Phone | (713) 300-5160 |
| Web | https://moleculin.com |
Moleculin Biotech Management Efficiency
The company has return on total asset (ROA) of (0.5745) % which means that it has lost $0.5745 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.4149) %, meaning that it created substantial loss on money invested by shareholders. Moleculin Biotech's management efficiency ratios could be used to measure how well Moleculin Biotech manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.15 in 2024. Return On Capital Employed is likely to drop to -0.99 in 2024. At this time, Moleculin Biotech's Net Tangible Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 2.8 M in 2024, whereas Total Assets are likely to drop slightly above 35.4 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Victoria Rac | Bio Path Holdings | N/A | |
| Winston MBA | Pmv Pharmaceuticals | 48 | |
| Jeffery MD | Bio Path Holdings | N/A | |
| Timothy Mayer | NextCure | 59 | |
| Scott Anderson | Anebulo Pharmaceuticals | N/A | |
| Peter MBA | Bio Path Holdings | 75 | |
| Eric Easom | AN2 Therapeutics | 56 | |
| Alexandra MD | Avenue Therapeutics | 57 | |
| Sanjay Chanda | AN2 Therapeutics | 59 | |
| BSc FRCPC | Inhibikase Therapeutics | N/A | |
| Josh Eizen | AN2 Therapeutics | N/A | |
| Catherine Kelleher | Capricor Therapeutics | N/A | |
| Jason Davis | Virax Biolabs Group | 52 | |
| Roger Rush | Inhibikase Therapeutics | N/A | |
| Rex CFA | Anebulo Pharmaceuticals | 64 | |
| Cameron Shaw | Virax Biolabs Group | 37 | |
| Annie Rasmussen | Allarity Therapeutics | 67 | |
| James Foster | Virax Biolabs Group | 39 | |
| Dan Williams | Inhibikase Therapeutics | N/A | |
| MBA BS | AN2 Therapeutics | 49 | |
| Paul MD | AN2 Therapeutics | 54 | |
Management Performance
| Return On Equity | -1.41 | ||||
| Return On Asset | -0.57 |
Moleculin Biotech Leadership Team
Elected by the shareholders, the Moleculin Biotech's board of directors comprises two types of representatives: Moleculin Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Moleculin. The board's role is to monitor Moleculin Biotech's management team and ensure that shareholders' interests are well served. Moleculin Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Moleculin Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Louis Ploth, Independent Advisor | ||
| Walter Klemp, Chairman, CoFounder | ||
| ScD MD, Senior Officer | ||
| Jonathan CPA, Executive CFO | ||
| Jacqueline Northcut, Consultant | ||
| Donald Picker, Chief Officer | ||
| Waldemar Priebe, Founding CoFounder | ||
| FACP MD, Chief Annamycin | ||
| MD FACP, Chief Annamycin | ||
| MBA MD, European Officer |
Moleculin Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Moleculin Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.41 | ||||
| Return On Asset | -0.57 | ||||
| Current Valuation | (819.83 K) | ||||
| Shares Outstanding | 3 M | ||||
| Shares Owned By Insiders | 3.30 % | ||||
| Shares Owned By Institutions | 15.34 % | ||||
| Number Of Shares Shorted | 122.38 K | ||||
| Price To Earning | (3.81) X | ||||
| Price To Book | 1.10 X | ||||
| EBITDA | (29.5 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Moleculin Stock Analysis
When running Moleculin Biotech's price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.